Avadel Pharmaceuticals Q2 EPS $(0.83) May Not be Comparable To $(0.38) Estimate, Sales $1.50M Beat $630.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Avadel Pharmaceuticals reported Q2 losses of $(0.83) per share, missing the analyst consensus estimate of $(0.38) by 118.42 percent. However, the company's quarterly sales of $1.50 million beat the analyst consensus estimate of $630.00 thousand by 137.46 percent.
August 09, 2023 | 11:09 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Avadel Pharmaceuticals' Q2 earnings per share missed estimates by a significant margin, but sales exceeded expectations.
Avadel Pharmaceuticals' Q2 earnings per share missed the consensus estimate by a significant margin, which could negatively impact investor sentiment and the stock price. However, the company's sales exceeded estimates, which could offset some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100